UnitedHealth Group Inc. (NYSE:UNH) reportedly announced on Tuesday that it will remove AbbVie Inc.’s (NYSE:ABBV) blockbuster drug Humira from some of its preferred reimbursement lists starting January ...
Credit: Celltrion. Yuflyma, a tumor necrosis factor blocker, was approved in May 2023 as a biosimilar to Humira. Similar PK, efficacy, safety, and immunogenicity data were observed between the ...
Think a friend or colleague should be getting this newsletter? Share this link with them to sign up. Good morning! Sales of AbbVie's Humira are plummeting as the once-top-selling drug fights ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback